We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more
It appears to be the day for biotechs as yet another company in the space has caught our attention during Tuesday’s session. Earlier in the day, an Illinois-based biotech To read the full...
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure...
Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel, Jan...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.82 | -37.1040723982 | 2.21 | 2.24 | 1.15 | 1095478 | 1.64864791 | CS |
4 | -2.57 | -64.898989899 | 3.96 | 4.59 | 1.15 | 387335 | 2.2374887 | CS |
12 | -1.55 | -52.7210884354 | 2.94 | 4.59 | 1.15 | 178623 | 2.56588665 | CS |
26 | 0.04 | 2.96296296296 | 1.35 | 4.59 | 1.15 | 126546 | 2.57580701 | CS |
52 | -1.46 | -51.2280701754 | 2.85 | 4.59 | 1.15 | 74692 | 2.53846075 | CS |
156 | -9.5 | -87.2359963269 | 10.89 | 13.95 | 1.15 | 86693 | 6.84604097 | CS |
260 | -7.37 | -84.1324200913 | 8.76 | 44.9 | 1.15 | 158239 | 9.88641698 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions